Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075400 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00075400: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00075400 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075400, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075400
The ClinicalTrials.gov registry entry for NCT00075400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00075400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075400 about?
NCT00075400 is a clinical study titled "Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer". This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes n...
What is the current status of trial NCT00075400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2004-01. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00075400?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00075400?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.